• HOME
  • ABOUT US
    • ABOUT THE COMPANY
    • THE TEAM
    • CHIEF EXECUTIVE OFFICER
    • CHIEF PHYSICIAN ADVISOR
    • CLINICAL NEUROSCIENCE
    • BIOTECHNOLOGY ADVISOR
    • COMPANY PRESIDENT
    • CHIEF FINANCIAL OFFICER
  • FORZA™
    • ABOUT FORZA™
    • THE STORY
    • THE SOURCE
    • THE PLAN
    • CALORIE RESTRICTION
    • VIRTUAL LIBRARY
  • REVIEWS
    • THE REVIEWS
    • IN LONG COVID
    • IN ALZHEIMER'S DISEASE
    • IN PARKINSON'S DISEASE
    • IN LEWY BODY DEMENTIA
    • IN MULTIPLE SCLEROSIS
    • IN DIABETES
    • IN LUPUS ERYTHEMATOSUS
    • IN SPINAL CORD INJURY
    • IN ARTHRITIS & PAIN
    • IN MIGRAINE & DEPRESSION
    • INFLAMMATION & INSOMNIA
  • WEBINARS
    • WEBINAR GALLERY
    • THE BIOLOGY OF AGING
    • ALZHEIMER'S DISEASE
    • PARKINSON'S DISEASE
    • DEPRESSION
    • FRONTOTEMPORAL DEMENTIAS
    • MULTIPLE SYSTEM ATROPHY
  • CONTACT US
  • Altro
    • HOME
    • ABOUT US
      • ABOUT THE COMPANY
      • THE TEAM
      • CHIEF EXECUTIVE OFFICER
      • CHIEF PHYSICIAN ADVISOR
      • CLINICAL NEUROSCIENCE
      • BIOTECHNOLOGY ADVISOR
      • COMPANY PRESIDENT
      • CHIEF FINANCIAL OFFICER
    • FORZA™
      • ABOUT FORZA™
      • THE STORY
      • THE SOURCE
      • THE PLAN
      • CALORIE RESTRICTION
      • VIRTUAL LIBRARY
    • REVIEWS
      • THE REVIEWS
      • IN LONG COVID
      • IN ALZHEIMER'S DISEASE
      • IN PARKINSON'S DISEASE
      • IN LEWY BODY DEMENTIA
      • IN MULTIPLE SCLEROSIS
      • IN DIABETES
      • IN LUPUS ERYTHEMATOSUS
      • IN SPINAL CORD INJURY
      • IN ARTHRITIS & PAIN
      • IN MIGRAINE & DEPRESSION
      • INFLAMMATION & INSOMNIA
    • WEBINARS
      • WEBINAR GALLERY
      • THE BIOLOGY OF AGING
      • ALZHEIMER'S DISEASE
      • PARKINSON'S DISEASE
      • DEPRESSION
      • FRONTOTEMPORAL DEMENTIAS
      • MULTIPLE SYSTEM ATROPHY
    • CONTACT US
  • HOME
  • ABOUT US
    • ABOUT THE COMPANY
    • THE TEAM
    • CHIEF EXECUTIVE OFFICER
    • CHIEF PHYSICIAN ADVISOR
    • CLINICAL NEUROSCIENCE
    • BIOTECHNOLOGY ADVISOR
    • COMPANY PRESIDENT
    • CHIEF FINANCIAL OFFICER
  • FORZA™
    • ABOUT FORZA™
    • THE STORY
    • THE SOURCE
    • THE PLAN
    • CALORIE RESTRICTION
    • VIRTUAL LIBRARY
  • REVIEWS
    • THE REVIEWS
    • IN LONG COVID
    • IN ALZHEIMER'S DISEASE
    • IN PARKINSON'S DISEASE
    • IN LEWY BODY DEMENTIA
    • IN MULTIPLE SCLEROSIS
    • IN DIABETES
    • IN LUPUS ERYTHEMATOSUS
    • IN SPINAL CORD INJURY
    • IN ARTHRITIS & PAIN
    • IN MIGRAINE & DEPRESSION
    • INFLAMMATION & INSOMNIA
  • WEBINARS
    • WEBINAR GALLERY
    • THE BIOLOGY OF AGING
    • ALZHEIMER'S DISEASE
    • PARKINSON'S DISEASE
    • DEPRESSION
    • FRONTOTEMPORAL DEMENTIAS
    • MULTIPLE SYSTEM ATROPHY
  • CONTACT US

David Ristenpart - Chief Financial Officer

History

With a strong background in manufacturing and marketing in Southern California, and having been a co-founder of FuturaGene, Inc. with Dr. Bruno Ruggiero in 2001, David has remained in either an active management role or as a contributing “angel investor” in virtually every commercial venture involving, among others, the Osmotin protein, since its valuation was first conceptualised.

Legacy

As CFO of 9th Dimension Biotech Inc., David is well positioned to direct the production and commercialisation aspects of 9D’s product pipeline. 

Vision

David co-founded 9D with the goal of advancing key technologies to offer tangible solutions to major human health and agricultural issues. 

CONTACT
  • HOME
  • CALORIE RESTRICTION
  • VIRTUAL LIBRARY

Copyright © 2024

9th Dimension Biotech, Inc.

All Rights Reserved.

Gestito da

This site uses cookies to offer you a better browsing experience

We use cookies to analyze website traffic and optimize user experience.
By accepting, you agree that your data will be aggregated with the data of all other users.

Accept